Can this new approach to medicine protect us from future viruses and become the magic bullet in the battle against cancer, HIV and other deadly diseases?
Streamed live: June 16, 2022 at 12:00 p.m.
When COVID-19 rampaged through the world in early 2020, scientists raced to develop vaccines built around the power of mRNA technology to trigger our immune systems and offer life-saving protection. Can this new approach to medicine protect us from future viruses and become the magic bullet in the battle against cancer, HIV and other deadly diseases? And how can we ensure that communities all over the world benefit equally from these technologies?
In this episode of the Made by McGill alumni webcast, we’ll hear from the McGill graduates behind Moderna and some of the University’s researchers who are working on the front lines to develop new mRNA therapies and to understand their implications for equity and global health.
With:
Noubar Afeyan, BEng’83, DSc’22, Founder and CEO, Flagship Pioneering; Co-founder and Chairman of Moderna
Avak Kahvejian, BSc’97, PhD’04, General Partner, Flagship Pioneering
Jerry Pelletier, BSc’81, PhD’88, Professor, Department of Biochemistry and Gerald Bronfman Department of Oncology; member, Rosalind and Morris Goodman Cancer Institute
Amélie Quesnel-Vallée, Professor, Departments of Sociology and Epidemiology, Biostatistics and Occupational Health; Canada Research Chair in Policies and Health Inequalities
Moderated by Derek Cassoff, Managing Director, Communications, McGill University Advancement
